Publications

Patents

Method of diagnosis and treatment: WO 2014/012147 A1

Publications

Konda SK, Maliki R, McGrath S, Parker BS, Robinson T, Spurling A, Cheong A, Lock P, Pigram PJ, Phillips DR, Wallace L, Day AI, Collins JG and Cutts SM (2017) Encapsulation of mitoxantrone within cucurbit[8]uril decreases toxicity and enhances survival in a mouse model of cancer, ACS Med Chem Lett., 8(5): 538-542.

Touati N, Tryfonidis K, Caramia F, Bonnefoi H, Cameron D, Slaets L, Parker BS and Loi S (2016) Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: investigating innate immunity as a tumor suppressor in breast cancer, Eur J Cancer, doi: 10.1093/annonc/mdw365.35.

Wen SW, Sceneay J, Lima LG, Wong CS, Becker M, Krumeich S, Lobb RJ, Castillo V, Wong KN, Ellis S, Parker BS and Möller A (2016) The biodistribution and immune suppressive effects of breast cancer-derived exosomes, Cancer Res.,76(23): 6816-27.

Edgington-Mitchell LE, Wartmann T, Fleming AK, Gocheva G, van der Linden WA, Withana NP, Verdoes M, Aurelio L, Edgington-Mitchell D, Lieu T, Parker BS, Graham B, Reinheckel T, Furness JB, Joyce JA, Storz P, Halangk W, Bogyo M and Bunnett NW (2016) Legumain is activated in macrophages during pancreatitis, Am J Physiol Gastrointest Liver Physiol., 311(3): G548-60.

Parker BS*, Rautela J and Hertzog P* (2016) Antitumour actions of type I interferons: implications for cancer therapy, Nat Rev Cancer, 16(3): 131-44.

Rautela J, Baschuk N, Slaney C, Jayatilleke K, Xiao K, Bidwell BN, Lucas EC, Hawkins ED, Lock P, Wong CS, Chen W, Anderson RL, Hertzog PJ, Andrews DM, Möller A and Parker BS (2015) Loss of host type-I IFN signaling accelerates metastasis and impairs NK cell anti-tumor function in multiple models of breast cancer, Cancer Immunol Res., 3(11): 1207-17.

Wong CS, Chen A, Liu MC, Parker BS and Möller A (2015) Loss of Siah2 does not impact angiogenic potential of murine endothelial cells, Microvasc Res., doi: 10.1016/j.mvr.2015.08.003.

Edgington-Mitchell L, Rautela J, Duivenvoorden HM, Jayatilleke KM, van der Linden WA, Verdoes M, Bogyo M and Parker BS (2015) Cysteine cathepsin activity suppresses osteoclatogenesis of myeloid-derived suppressor cells in breast cancer, Oncotarget, 6(29): 27008-22.

Croucher PI, Parker BS, Corcoran N and Rogers MJ (2015) Bone turnover markers and prostate cancer: not just a measure of bone disease? Eur Urol., 68(1): 51-52.

Baschuk N, Rautela J and Parker BS (2015) Bone specific immunity and its impact on metastasis, Bonekey Rep., 4:665, doi: 10.1038/bonekey.2015.32.

Gangoda L, Keerthikumar S, Fonseka P, Edgington LE, Ang CS, Ozcitti C, Bogyo M, Parker BS and Mathivanan S (2015) Inhibition of cathepsin proteases attenuates migration and sensitizes aggressive N-Myc amplified human neuroblastoma cells to doxorubicin, Oncotarget, 6(13): 1175-90.

Cao Y, Slaney CY, Bidwell BN, Parker BS, Johnstone CN, Rautela J, Eckhardt BL and Anderson RL (2014) Bone morphogenetic protein 4 inhibits breast cancer metastasis by blocking myeloid derived suppressor cell activity, Cancer Res., 74(18): 5091-102.

Edgington-Mitchell LE and Parker BS (2014) Disparate roles for myeloid-derived suppressor cells in cancer metastasis, Cancer Forum, 38(2): 107-11.

Slaney CY, Rautela J and Parker BS (2013) The emerging role of immune surveillance in dictating metastatic spread in breast cancer, Cancer Res., 73(19): 5852-57.

Fung KY, Mangan NE, Cumming H, Horvat JC, Mayall JR, Stifter S, De Weerd N, Roisman LC, Rossjohn J,  Robertson S, Schjenken J, Parker BS, Gargett C, Nguyen HPT, Carr DJ,  Hansbro PM and Hertzog PJ (2013) Interferon epsilon is a novel, innate cytokine that protects the reproductive tract from viral and bacterial infection, Science, 339(6123): 1088-92.

Slaney CY, Möller A, Hertzog PJ and Parker BS (2013) The role of Type I interferons in immunoregulation of breast cancer metastasis to bone, Oncoimmunology, 2(1): e22339.

Sceneay J, Parker BS, Smyth MJ and Möller A (2013) Hypoxia-driven immunosuppression contributes to the premetastatic niche, Oncoimmunology, 2(1): e22355.

Bidwell BN, Slaney C, Withana NP, Forster S, Cao Y, Mikeska T, Andrews D, Mangan N, Loi S, Samarajiwa SA, de Weerd NA, Gould J, Argani P, Möller A, Smyth M, Anderson RL, Hertzog P and Parker BS (2012) Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis via immune escape, Nat Med., 18(8): 1224-31.

Sceneay J, Chow MT, Chen A, Halse HM, Wong CSF, Andrews DM, Sloan EK, Parker BS, Bowtell DD, Smyth MJ and Möller A (2012) Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the pre-metastatic niche, Cancer Res., 72(16): 3906-11.

Eckhardt BL, Francis PA, Parker BS* and Anderson RL* (2012) Strategies for the discovery and development of therapies for metastatic breast cancer, Nat Rev Drug Discov., 11(6): 479-97.

Wong CSF, Sceneay J, House CM, Halse HM, Liu MCP, George J, Hunnam TCU, Parker BS, Haviv I, Ronai Z, Cullinane C, Bowtell DD and Möller A (2012) Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy, Cancer Res., 72(7): 1694-704.

Withana NP, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB, Bidwell BN, Edgington L, Wang L, Moin K, Sloane BF, Anderson RL, Bogyo MS and Parker BS (2012) Cathepsin B inhibition limits bone metastasis in breast cancer, Cancer Res., 72(5): 1199-209.

Kusuma N, Denoyer D, Eble JA, Redvers RP, Parker BS, Pelzer R, Anderson RL and Pouliot N (2012) Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis, Int J Cancer, 130(3): 555-66.

*Contributed equally to work.